'Wrapping' Gleevec fights drug-resistant cancer
... The wrapping version of the drug known as WBZ-7 was created, produced and tested by three research teams, one headed by Ariel Fernandez from Rice University and the other two headed respectively by William Bo...5-year study shows Gleevec's potency against chronic myeloid leukemia
... Howard Hughes Medical Institute investigator Brian Druker, who led the five-year study, said the findings demonstrate Gleevec's effectiveness against the formerly fatal disease. He noted that the study's results emphasize the value of the new approach to developing cancer drugs that target the specific genetic malfunctions that drive cancer.... Druker,...Five-year study by OHSU Cancer Institute shows Gleevec's excellent survival rate
... ... "We've completely changed the outlook for patients with this disease. Before Gleevec, patients were fortunate if they lived five years. Now, we've given patients a hopef...New drug target might sidestep gleevec resistance, Jefferson scientists show
... A drug that could turn on the gene that makes the...Jefferson scientists show 'miracle' cancer drug Gleevec can be toxic to the heart
(Philadelphia) Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart. Not only that, but other similarly based drugs called tyrosine kinase inhibitors could lead to heart problems as well, say researchers at the Center for Translational Medicine at Jefferson Medical College in Philadelphia. .....Five-year study confirms Gleevec's long-term benefits
ATLANTA, Ga. -- People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health & Science University Cancer Institute researchers. ...... The study was led by Charles Blanke, M.D., leader of the OHSU Cancer Institute Solid Tumors Program, with colleagues at OHSU, Dan...AMN107 has potent activity in leukemia resistant to Gleevec
The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center (meeting abstract #37).... ... At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in ou...Molecular testing in patients with rare cancer predicts response to Gleevec
PORTLAND, Ore. -- Patients with gastrointestinal stromal tumors (GIST) who have a particular genetic mutation are more likely to respond to Gleevec (imatinib) than those without the mutation, according to OHSU study results showcased at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO). The results confirm previous observations and provide a foundation for molecular test...Increasing benefit seen in novel drug that treats Gleevec resistance
ANAHEIM - An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting....... The drug, AMN107, is showing an increasingly strong benefit as doses are bein...